[Polycystic kidney disease: Pathogenesis, pathophysiology, and therapy].
Ubara
Yoshifumi
Y
Nephrology Center, Toranomon Hospital.
Yamaguchi
Tamio
T
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004621:Embolization, Therapeutic; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000502:physiology; D009154:Mutation; D015282:Octreotide / Q000627:therapeutic use; D007690:Polycystic Kidney Diseases / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D011506:Proteins / Q000235:genetics / Q000502:physiology; D012077:Renal Artery; D050396:TRPP Cation Channels; D014667:Vasopressins / Q000627:therapeutic use
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002118:Calcium; D002121:Calcium Channel Blockers; D008565:Membrane Proteins; D015282:Octreotide; D011506:Proteins; D050396:TRPP Cation Channels; D014667:Vasopressins